Zacks Research Lowers Earnings Estimates for Globus Medical

Globus Medical, Inc. (NYSE:GMED) – Stock analysts at Zacks Research lowered their Q2 2025 EPS estimates for shares of Globus Medical in a report issued on Wednesday, July 23rd. Zacks Research analyst R. Department now expects that the medical device company will post earnings of $0.76 per share for the quarter, down from their prior estimate of $0.78. The consensus estimate for Globus Medical’s current full-year earnings is $3.44 per share. Zacks Research also issued estimates for Globus Medical’s FY2025 earnings at $3.14 EPS, Q1 2026 earnings at $0.81 EPS, Q2 2026 earnings at $0.93 EPS, Q4 2026 earnings at $0.84 EPS, FY2026 earnings at $3.57 EPS, Q1 2027 earnings at $0.84 EPS and FY2027 earnings at $4.02 EPS.

Globus Medical (NYSE:GMED) last released its earnings results on Thursday, May 8th. The medical device company reported $0.68 EPS for the quarter, missing the consensus estimate of $0.74 by ($0.06). The business had revenue of $598.12 million for the quarter, compared to the consensus estimate of $629.74 million. Globus Medical had a net margin of 7.39% and a return on equity of 10.52%. Globus Medical’s revenue for the quarter was down 1.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.72 EPS.

A number of other research firms have also weighed in on GMED. JMP Securities reissued a “market perform” rating on shares of Globus Medical in a research note on Tuesday, May 27th. Morgan Stanley lowered their price objective on Globus Medical from $75.00 to $68.00 and set an “overweight” rating for the company in a research report on Tuesday, July 15th. Piper Sandler dropped their price objective on Globus Medical from $100.00 to $80.00 and set an “overweight” rating for the company in a research note on Friday, May 9th. Truist Financial cut their target price on shares of Globus Medical from $80.00 to $68.00 and set a “hold” rating on the stock in a report on Monday, May 12th. Finally, BTIG Research reaffirmed a “neutral” rating on shares of Globus Medical in a research note on Tuesday, May 27th. Five investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $90.09.

Globus Medical Stock Down 0.4%

NYSE GMED opened at $54.06 on Monday. The company has a 50-day simple moving average of $57.90 and a two-hundred day simple moving average of $70.45. Globus Medical has a 12-month low of $51.87 and a 12-month high of $94.93. The firm has a market cap of $7.32 billion, a price-to-earnings ratio of 40.34, a PEG ratio of 1.59 and a beta of 1.19.

Globus Medical declared that its Board of Directors has initiated a stock repurchase plan on Thursday, May 15th that authorizes the company to buyback $500.00 million in outstanding shares. This buyback authorization authorizes the medical device company to reacquire up to 6.3% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.

Hedge Funds Weigh In On Globus Medical

A number of hedge funds and other institutional investors have recently made changes to their positions in GMED. Farther Finance Advisors LLC boosted its holdings in Globus Medical by 145.5% in the first quarter. Farther Finance Advisors LLC now owns 405 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 240 shares in the last quarter. Larson Financial Group LLC raised its holdings in Globus Medical by 1,007.7% in the 1st quarter. Larson Financial Group LLC now owns 432 shares of the medical device company’s stock worth $32,000 after purchasing an additional 393 shares in the last quarter. Parallel Advisors LLC raised its holdings in Globus Medical by 62.1% in the 1st quarter. Parallel Advisors LLC now owns 504 shares of the medical device company’s stock worth $37,000 after purchasing an additional 193 shares in the last quarter. Versant Capital Management Inc lifted its position in shares of Globus Medical by 932.1% in the 1st quarter. Versant Capital Management Inc now owns 547 shares of the medical device company’s stock worth $40,000 after purchasing an additional 494 shares during the period. Finally, Whittier Trust Co. boosted its stake in shares of Globus Medical by 46.5% during the 1st quarter. Whittier Trust Co. now owns 580 shares of the medical device company’s stock valued at $42,000 after purchasing an additional 184 shares in the last quarter. Institutional investors own 95.16% of the company’s stock.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.